Structure-activity relationships of recombinant hirudins
Review published in Seminars in Thrombosis and Hemostasis (1991)
Abstract
The complex formation between thrombin and hirudin is unique among other serine proteinase-inhibitor complexes. The serpines occupy the specificity pocket of the active site of the target enzyme with an amino acid residue corresponding to the specificity of the enzyme at the P1 site of the substrate. In contrast, the Thr2 residue of hirudin approaches only the entrance of the pocket. The peptide chain of the inhibitors D-Phe-Pro-ArgCH2Cl and NAPAP is antiparallel to the enzyme backbone, whereas the N-terminal amino acids of hirudin run parallel. These unexpected interactions seem to contribute to a greater extent to the tight binding than the ionic interactions of the hirudin tail with the fibrinogen binding site of thrombin. Obviously, these interactions account for the unique selectivity of hirudin for thrombin.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Reviews how recombinant hirudin's N-terminal Thr2 contacts the active-site entrance running parallel to thrombin's backbone, while ionic interactions of the C-terminal hirudin tail with thrombin's fibrinogen binding site provide additional selectivity.
Warum dies für die Hirudotherapie relevant ist
This work examines the molecular interactions in the complex formation between thrombin and hirudin, describing how hirudin's N-terminal amino acids run parallel to the enzyme backbone—in contrast to other serine proteinase-inhibitor complexes—and how the Thr2 residue approaches only the entrance of the specificity pocket. The abstract indicates these interactions contribute more to tight binding than the ionic interactions of the hirudin tail with the fibrinogen binding site of thrombin, accounting for hirudin's unique selectivity for thrombin. This is relevant to ASH's domain as it provides molecular-level insight into the hirudin-thrombin interaction. Caveat: the scope is limited to biochemical and molecular characterization, with no clinical, whole-organism, or therapeutic application data presented.
Zitation
Structure-activity relationships of recombinant hirudins.
Stürzebecher J, Walsmann P · Seminars in thrombosis and hemostasis, 1991
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 26, 2026 · Letzte Aktualisierung der Website: June 18, 2026